カテゴリー： Market Monitor Global, 世界, 医療/バイオ

肝胆道疾患向けウルソデオキシコール酸製剤の世界市場見通し2023年-2029年

◆英語タイトル：Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが発行した調査報告書（MMG23FB2519）

◆商品コード：MMG23FB2519
◆発行会社（リサーチ会社）：Market Monitor Global
◆発行日：2023年2月
◆ページ数：72
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後2-3営業日）
◆調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,250 ⇒換算￥494,000	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD4,225 ⇒換算￥642,200	見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）	USD4,875 ⇒換算￥741,000	見積依頼/購入/質問フォーム

★Market Monitor Globalに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

当調査レポートは次の情報を含め、世界の肝胆道疾患向けウルソデオキシコール酸製剤市場規模と予測を収録しています。・世界の肝胆道疾患向けウルソデオキシコール酸製剤市場：売上、2018年-2023年、2024年-2029年
・世界の肝胆道疾患向けウルソデオキシコール酸製剤市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の肝胆道疾患向けウルソデオキシコール酸製剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「カプセル」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

肝胆道疾患向けウルソデオキシコール酸製剤のグローバル主要企業は、Dr. Falk Pharma、Daewoong Pharmaceutical、Teva、Humanwell、Mitsubishi Tanabe Pharma、Lannett、Mylan、Bruschettini、Impax、Shanghai Pharma、Grindeksなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、肝胆道疾患向けウルソデオキシコール酸製剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の肝胆道疾患向けウルソデオキシコール酸製剤市場：タイプ別、2018年-2023年、2024年-2029年
世界の肝胆道疾患向けウルソデオキシコール酸製剤市場：タイプ別市場シェア、2022年
・カプセル、錠剤

世界の肝胆道疾患向けウルソデオキシコール酸製剤市場：用途別、2018年-2023年、2024年-2029年
世界の肝胆道疾患向けウルソデオキシコール酸製剤市場：用途別市場シェア、2022年
・原発性胆汁性肝硬変（PBC）、胆石、その他

世界の肝胆道疾患向けウルソデオキシコール酸製剤市場：地域・国別、2018年-2023年、2024年-2029年
世界の肝胆道疾患向けウルソデオキシコール酸製剤市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における肝胆道疾患向けウルソデオキシコール酸製剤のグローバル売上、2018年-2023年
・主要企業における肝胆道疾患向けウルソデオキシコール酸製剤のグローバル売上シェア、2022年
・主要企業における肝胆道疾患向けウルソデオキシコール酸製剤のグローバル販売量、2018年-2023年
・主要企業における肝胆道疾患向けウルソデオキシコール酸製剤のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Dr. Falk Pharma、Daewoong Pharmaceutical、Teva、Humanwell、Mitsubishi Tanabe Pharma、Lannett、Mylan、Bruschettini、Impax、Shanghai Pharma、Grindeks

*************************************************************

・調査・分析レポートの概要
肝胆道疾患向けウルソデオキシコール酸製剤市場の定義
市場セグメント
世界の肝胆道疾患向けウルソデオキシコール酸製剤市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の肝胆道疾患向けウルソデオキシコール酸製剤市場規模
世界の肝胆道疾患向けウルソデオキシコール酸製剤市場規模：2022年 VS 2029年
世界の肝胆道疾患向けウルソデオキシコール酸製剤市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの肝胆道疾患向けウルソデオキシコール酸製剤の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の肝胆道疾患向けウルソデオキシコール酸製剤製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：カプセル、錠剤
肝胆道疾患向けウルソデオキシコール酸製剤のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：原発性胆汁性肝硬変（PBC）、胆石、その他
肝胆道疾患向けウルソデオキシコール酸製剤の用途別グローバル売上・予測

・地域別市場分析
地域別肝胆道疾患向けウルソデオキシコール酸製剤市場規模 2022年と2029年
地域別肝胆道疾患向けウルソデオキシコール酸製剤売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Dr. Falk Pharma、Daewoong Pharmaceutical、Teva、Humanwell、Mitsubishi Tanabe Pharma、Lannett、Mylan、Bruschettini、Impax、Shanghai Pharma、Grindeks
...

Ursodeoxycholic acid is a bile acid used for the treatment of primary biliary cirrhosis (PBC), dissolution of radiolucent gallstones in patients with a functioning gallbladder, and treatment of hepatobiliary disorders associated with cystic fibrosis in pediatric patients.
This report aims to provide a comprehensive presentation of the global market for Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases. This report contains market size and forecasts of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases in global, including the following market information:
Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases companies in 2022 (%)
The global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Capsule Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases include Dr. Falk Pharma, Daewoong Pharmaceutical, Teva, Humanwell, Mitsubishi Tanabe Pharma, Lannett, Mylan, Bruschettini and Impax, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
[Total Market by Segment]
Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Segment Percentages, by Type, 2022 (%)
Capsule
Tablet
Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Segment Percentages, by Application, 2022 (%)
Primary Biliary Cirrhosis(PBC)
Gallstones
Others
Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases revenues share in global market, 2022 (%)
Key companies Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Dr. Falk Pharma
Daewoong Pharmaceutical
Teva
Humanwell
Mitsubishi Tanabe Pharma
Lannett
Mylan
Bruschettini
Impax
Shanghai Pharma
Grindeks
Outline of Major Chapters:
Chapter 1: Introduces the definition of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases, market overview.
Chapter 2: Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases market size in revenue and volume.
Chapter 3: Detailed analysis of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

❖ レポートの目次 ❖

1 Introduction to Research & Analysis Reports
1.1 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Overall Market Size
2.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size: 2022 VS 2029
2.2 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales: 2018-2029
3 Company Landscape
3.1 Top Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Players in Global Market
3.2 Top Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Companies Ranked by Revenue
3.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue by Companies
3.4 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales by Companies
3.5 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Product Type
3.8 Tier 1, Tier 2 and Tier 3 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Players in Global Market
3.8.1 List of Global Tier 1 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Companies
3.8.2 List of Global Tier 2 and Tier 3 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size Markets, 2022 & 2029
4.1.2 Capsule
4.1.3 Tablet
4.2 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue & Forecasts
4.2.1 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2018-2023
4.2.2 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2024-2029
4.2.3 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share, 2018-2029
4.3 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales & Forecasts
4.3.1 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2018-2023
4.3.2 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2024-2029
4.3.3 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share, 2018-2029
4.4 By Type – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2022 & 2029
5.1.2 Primary Biliary Cirrhosis(PBC)
5.1.3 Gallstones
5.1.4 Others
5.2 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue & Forecasts
5.2.1 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2018-2023
5.2.2 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2024-2029
5.2.3 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share, 2018-2029
5.3 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales & Forecasts
5.3.1 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2018-2023
5.3.2 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2024-2029
5.3.3 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share, 2018-2029
5.4 By Application – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2022 & 2029
6.2 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue & Forecasts
6.2.1 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2018-2023
6.2.2 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2024-2029
6.2.3 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue Market Share, 2018-2029
6.3 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales & Forecasts
6.3.1 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2018-2023
6.3.2 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2024-2029
6.3.3 By Region – Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2018-2029
6.4.2 By Country – North America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2018-2029
6.4.3 US Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.4.4 Canada Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.4.5 Mexico Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2018-2029
6.5.2 By Country – Europe Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2018-2029
6.5.3 Germany Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.5.4 France Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.5.5 U.K. Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.5.6 Italy Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.5.7 Russia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.5.8 Nordic Countries Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.5.9 Benelux Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2018-2029
6.6.2 By Region – Asia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2018-2029
6.6.3 China Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.6.4 Japan Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.6.5 South Korea Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.6.6 Southeast Asia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.6.7 India Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2018-2029
6.7.2 By Country – South America Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2018-2029
6.7.3 Brazil Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.7.4 Argentina Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales, 2018-2029
6.8.3 Turkey Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.8.4 Israel Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.8.5 Saudi Arabia Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
6.8.6 UAE Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Dr. Falk Pharma
7.1.1 Dr. Falk Pharma Company Summary
7.1.2 Dr. Falk Pharma Business Overview
7.1.3 Dr. Falk Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.1.4 Dr. Falk Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.1.5 Dr. Falk Pharma Key News & Latest Developments
7.2 Daewoong Pharmaceutical
7.2.1 Daewoong Pharmaceutical Company Summary
7.2.2 Daewoong Pharmaceutical Business Overview
7.2.3 Daewoong Pharmaceutical Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.2.4 Daewoong Pharmaceutical Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.2.5 Daewoong Pharmaceutical Key News & Latest Developments
7.3 Teva
7.3.1 Teva Company Summary
7.3.2 Teva Business Overview
7.3.3 Teva Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.3.4 Teva Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.3.5 Teva Key News & Latest Developments
7.4 Humanwell
7.4.1 Humanwell Company Summary
7.4.2 Humanwell Business Overview
7.4.3 Humanwell Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.4.4 Humanwell Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.4.5 Humanwell Key News & Latest Developments
7.5 Mitsubishi Tanabe Pharma
7.5.1 Mitsubishi Tanabe Pharma Company Summary
7.5.2 Mitsubishi Tanabe Pharma Business Overview
7.5.3 Mitsubishi Tanabe Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.5.4 Mitsubishi Tanabe Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.5.5 Mitsubishi Tanabe Pharma Key News & Latest Developments
7.6 Lannett
7.6.1 Lannett Company Summary
7.6.2 Lannett Business Overview
7.6.3 Lannett Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.6.4 Lannett Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.6.5 Lannett Key News & Latest Developments
7.7 Mylan
7.7.1 Mylan Company Summary
7.7.2 Mylan Business Overview
7.7.3 Mylan Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.7.4 Mylan Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.7.5 Mylan Key News & Latest Developments
7.8 Bruschettini
7.8.1 Bruschettini Company Summary
7.8.2 Bruschettini Business Overview
7.8.3 Bruschettini Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.8.4 Bruschettini Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.8.5 Bruschettini Key News & Latest Developments
7.9 Impax
7.9.1 Impax Company Summary
7.9.2 Impax Business Overview
7.9.3 Impax Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.9.4 Impax Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.9.5 Impax Key News & Latest Developments
7.10 Shanghai Pharma
7.10.1 Shanghai Pharma Company Summary
7.10.2 Shanghai Pharma Business Overview
7.10.3 Shanghai Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.10.4 Shanghai Pharma Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.10.5 Shanghai Pharma Key News & Latest Developments
7.11 Grindeks
7.11.1 Grindeks Company Summary
7.11.2 Grindeks Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Business Overview
7.11.3 Grindeks Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Major Product Offerings
7.11.4 Grindeks Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Sales and Revenue in Global (2018-2023)
7.11.5 Grindeks Key News & Latest Developments
8 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Production Capacity, Analysis
8.1 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Production Capacity, 2018-2029
8.2 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Production Capacity of Key Manufacturers in Global Market
8.3 Global Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Supply Chain Analysis
10.1 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Industry Value Chain
10.2 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Upstream Market
10.3 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 肝胆道疾患向けウルソデオキシコール酸製剤の世界市場見通し2023年-2029年(Ursodeoxycholic Acid Drugs for Hepatobiliary Diseases Market, Global Outlook and Forecast 2023-2029)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

肝胆道疾患向けウルソデオキシコール酸製剤の世界市場見通し2023年-2029年

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp